Cellectar announces stock consolidation

Florham park, n.j., july 21, 2022 (globe newswire) -- cellectar biosciences, inc. (nasdaq: clrb), a late-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, today announced that, as authorized by its stockholders, the company is implementing a consolidation (reverse stock split) of its outstanding common shares on the basis of one (1) new common share for every ten (10) currently outstanding.
CLRB Ratings Summary
CLRB Quant Ranking